TY - EJOU AU - Butty, Vincent L. AU - Roux-Lombard, Pascale AU - Garbino, Jorge AU - Dayer, Jean-Michel AU - Ricou, Bara AU - Network, and the Geneva Sepsis TI - Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis T2 - European Cytokine Network PY - 2003 VL - 14 IS - 1 SN - 1952-4005 AB - Objectives: To investigate the effects of Lenercept®, a recombinant soluble TNF receptor p55 fused to an immunoglobulin heavy chain IgG1, on the balance of pro- and anti-inflammatory mediators in sepsis.
Design: Post hoc analysis of a subgroup of patients enrolled in a multicenter phase III, prospective, double-blind, placebo-controlled, randomized study of Lenercept ® in severe sepsis.
Setting: Surgical and medical intensive care units, and postoperative recovery room of a tertiary care teaching hospital.
Patients: A total of 57 patients were enrolled in the multicenter study in our center.
Intervention: Septic patients were randomly assigned to receive either Lenercept ® 0.125 mg/kg or placebo. The patients were followed for up to 28 days after randomization.
Measurements and main results: Circulating levels of TNF-α, IL-6, TNFsR75 and IL-1Ra were measured before and after treatment. The two groups were comparable with regard to age, gender and diagnosis distribution. The total level of TNF-α increased significantly in treated patients, compared to patients receiving placebo. The levels of the other inflammatory mediators did not differ between the two groups.
Conclusions: Lenercept ®-treated patients experienced a protracted TNF-a half-life, leading to higher total TNF-α levels throughout the study. However, the treatment had no effects on anti-inflammatory mediators. Therefore, peripheral inflammatory processes might not have been significantly modified by the treatment. This might account for the lack of efficacy this treatment in septic patients. KW - tumor necrosis factor KW - TNF-antagonist KW - cytokines KW - TNF receptor KW - sepsis DO -